Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

NANOTEST · Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

FP7Status: CLOSED1 April 200831 March 2012EU funding €2,994,383

Nanoparticles (NP) have unique, potentially beneficial properties, but their possible impact on human health has not been adequately assessed. The main goal of this proposal is to develop alternative high-throughput testing strategies using in vitro and in silico methods to assess the toxicological profile of NP used in medical diagnostics. Our specific aims are to: 1. Define NP properties and fully characterize NP to be used 2. Study NP interactions with molecules, cells and organs and develop in vitro methods to study the toxicological potential of NP 3. Validate in vitro findings in short-term in vivo models and study particle effects in animals and (ex vivo) in humans to assess individual susceptibility to NP 4. Develop in silico models of NP interactions Experimental work is structured in 4 WPs to address NP characterisation and key elements in evaluation of NP uptake, exposure and toxicology. NANOTEST integrates the investigation of toxicological properties and effects of NP in several target systems by developing a battery of in vitro assays using cell cultures, organotypic cell culture and small organ fragments (ex vivo) derived from different biological systems; blood, vascular system, liver, lung, placenta, digestive and central nervous systems. As NP action is likely to involve oxidative stress we will focus on the cross-cutting areas of inflammation, cellular toxicity, immunotoxicity, genotoxicity and related endpoints. Following development of SOP and generation of a common database and in parallel with in silico assays (QSAR, PBPK modelling), NanoTest will evaluate toxic effects and interactions of NP used in nanomedicine. Results will be validated in an experimental ethically approved in vivo model. The most advanced and standardised techniques will be adapted for automation and prepared for validation by ECVAM. Separate WPs will be dedicated to dissemination and to effective administrative and scientific management.

Consortium · 12 organisations

coordinator

STIFTELSEN NILU

NO · €578,430

participant

Université Paris Diderot-Paris 7

FR · €193,250

participant

KOBENHAVNS UNIVERSITET

DK · €188,670

participant

INSTITUTE OF OCCUPATIONAL MEDICINE

UK · €130,593

participant

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

CH · €215,750

participant

UNIVERSITA CA' FOSCARI VENEZIA

IT · €158,520

participant

ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES S.A.

ES · €308,509

participant

NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS""""

EL · €150,050

participant

UNIVERSITY HOSPITALS BRISTOL AND WESTON NHS FOUNDATION TRUST

UK · €188,196

participant

SLOVENSKA ZDRAVOTNICKA UNIVERZITA V BRATISLAVE

SK · €339,750

participant

ACONDICIONAMIENTO TARRASENSE ASSOCIACION

ES · €78,823

participant

JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION

BE · €463,842

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.